Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Anjana Grandhi"'
Autor:
Regino P. Gonzalez-Peralta, Stefan Wirth, Robert H. Squires, Frauke Mutschler, Thomas Lang, Malgorzata Pawlowska, Wojciech Sluzewski, Ewa Majda-Stanislawska, Bjorn Fischler, William F. Balistreri, Maureen M. Jonas, Niviann Blondet, Philip Rosenthal, Naim Alkhouri, Rene Romero, Anjana Grandhi, Patricia Castronuovo, Luzelena Caro, Lihong Du, Daniel I.S. Rosenbloom, Barbara A. Haber
Publikováno v:
Hepatology Communications, Vol 7, Iss 3, Pp e0031-e0031 (2023)
Background:. Approximately 3.5 million children and adolescents worldwide are chronically infected with HCV. This study uses pharmacokinetic modeling to identify pediatric doses of elbasvir/grazoprevir (EBR/GZR) that achieve plasma concentrations sim
Externí odkaz:
https://doaj.org/article/0efa3d17ae6a4abb80653349bdc6fcd4
Autor:
George J. Hanna, Karen Eves, Anjana Grandhi, Alejandro Afani Saud, Peter Sklar, Michael N. Robertson, Carolina Chahin Anania, Todd Correll, Edwin DeJesus, Christopher J. Bettacchi, Carey Hwang, Jean-Michel Molina, Yazdan Yazdanpanah, Stephanie O. Klopfer
Publikováno v:
The Lancet HIV. 8:e324-e333
Summary Background Islatravir is a nucleoside reverse transcriptase translocation inhibitor in development for the treatment and prevention of HIV-1 infection. We aimed to assess the efficacy and safety of islatravir-based regimens for the treatment
Autor:
Dominik J Wolf, John S. Bradley, Myra W. Popejoy, Paula M. Bokesch, Ellie Hershberger, Valeri A Digtyar, Christopher M. Tan, Yoshihiko Murata, Anjana Grandhi, Mary Beth Dorr, Mekki Bensaci, Antonio Arrieta
Publikováno v:
Pediatric Infectious Disease Journal. 39:814-823
Background We prospectively evaluated efficacy and safety of daptomycin versus active comparator in children with acute hematogenous osteomyelitis (AHO). Methods Randomized, controlled, double-blind, global, multicenter, phase 3 trial. Patients 1-17
Autor:
Jean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, Christopher Bettacchi, Carolina Chahin Anania, Stephanie O. Klopfer, Anjana Grandhi, Karen Eves, Deborah Hepler, Michael N. Robertson, Carey Hwang, George J. Hanna, Todd Correll
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 91(1)
Islatravir (MK-8591) is a nucleoside reverse transcriptase translocation inhibitor in development for treatment and prevention of HIV-1. We present efficacy and safety data for islatravir and doravirine (DOR) through 96 weeks of the phase 2b trial (N
Autor:
Anjana Grandhi, Hetty Waskin, Galia Rahav, Issam I Raad, Meinolf Karthaus, Dong-Gun Lee, Seongah Han, Juan Diego Vélez, Ronen Ben-Ami, Nikolay Klimko, Johan Maertens, Isabel Cristina Ramírez Sánchez, Shariq Haider, Liang-Piu Koh, Alfredo Ponce-de-León, Mary Motyl, Anne Sonet, Jianying Zhou
Publikováno v:
Lancet, Vol. 397, no. 10273, p. 499-509 (2021)
BACKGROUND: Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole.
Publikováno v:
Statistica Sinica.
In this paper, we consider the problem of simultaneously testing many two-sided hypotheses when rejections of null hypotheses are accompanied by claims of the direction of the alternative. The fundamental goal is to construct methods that control the
Autor:
Anjana Grandhi, Hong Liu, Ziv Ben-Ari, Joan R. Butterton, Shuyan Wan, Zhen Zeng, Kosh Agarwal, Stefan Zeuzem, Wei Gao, J.J. Li, Brian Fitzgerald, Feng Hsiu Su, Alexander J. Thompson, Eliav Barr, Wendy W. Yeh, Jan Gerstoft, Frank J. Dutko, Hsueh Cheng Huang, Janice Wahl, Huei Ling Chen, Alex Lund Laursen, Bach-Yen Nguyen, Eli Zuckerman, Graham R. Foster, Stuart K. Roberts, Rebeca M. Plank, Stephen Pianko, Doreen Fernsler, Edward Gane, Rafael Esteban, Michael N. Robertson
Publikováno v:
Gane, E J, Pianko, S, Roberts, S K, Thompson, A J, Zeuzem, S, Zuckerman, E, Ben-Ari, Z, Foster, G R, Agarwal, K, Laursen, A L, Gerstoft, J, Gao, W, Huang, H-C, Fitzgerald, B, Fernsler, D, Li, J J, Grandhi, A, Liu, H, Su, F-H, Wan, S, Zeng, Z, Chen, H-L, Dutko, F J, Nguyen, B-Y T, Wahl, J, Robertson, M N, Barr, E, Yeh, W W, Plank, R M, Butterton, J R & Esteban, R 2017, ' Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A) : two randomised, phase 2, open-label trials ', The Lancet. Gastroenterology & hepatology . https://doi.org/10.1016/S2468-1253(17)30159-0
BACKGROUND: New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed. The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bea6598b2c22e53dfccd71d17c4b9dc4
https://pure.au.dk/portal/da/publications/safety-and-efficacy-of-an-8week-regimen-of-grazoprevir-plus-ruzasvir-plus-uprifosbuvir-compared-with-grazoprevir-plus-elbasvir-plus-uprifosbuvir-in-participants-without-cirrhosis-infected-with-hepatitis-c-virus-genotypes-1-2-or-3-ccrest1-and-ccrest2-part-a(932ebad4-6854-4b23-91d5-ad304b095b06).html
https://pure.au.dk/portal/da/publications/safety-and-efficacy-of-an-8week-regimen-of-grazoprevir-plus-ruzasvir-plus-uprifosbuvir-compared-with-grazoprevir-plus-elbasvir-plus-uprifosbuvir-in-participants-without-cirrhosis-infected-with-hepatitis-c-virus-genotypes-1-2-or-3-ccrest1-and-ccrest2-part-a(932ebad4-6854-4b23-91d5-ad304b095b06).html
Autor:
Doreen Fernsler, Bach-Yen Nguyen, Wei Gao, Piero Luigi Almasio, Brynne Tannenbaum, Anjana Grandhi, Eric M. Yoshida, Maria Buti, Beat Muellhaupt, Joan R. Butterton, Rebeca M. Plank, Eliav Barr, Ligita Jancoriene, Brian L. Pearlman, Feng Hsiu Su, J.J. Li, Janice Wahl, Shuyan Wan, John M. Vierling, Hong Liu, Wendy W. Yeh, Aimee Shepherd, Savino Bruno, Hsueh Cheng Huang, Tarek Hassanein, Michael N. Robertson, Frank J. Dutko, Peter Ruane, Eric Lawitz
Background There is a need for hepatitis C virus (HCV) therapies with excellent efficacy across genotypes and in diverse populations. Part A of the C-CREST-1 and C-CREST-2 trials led to the selection of a three-drug regimen of grazoprevir (MK-5172; a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe3ee1d97513e34b0a56aec77c17448
https://www.zora.uzh.ch/id/eprint/146110/
https://www.zora.uzh.ch/id/eprint/146110/
Autor:
Mekki Bensaci, Myra Popejoy, John S. Bradley, Anjana Grandhi, Antonio Arrieta, Nicholas A. Kartsonis
Publikováno v:
Open Forum Infectious Diseases. 3
Publikováno v:
BMC Bioinformatics
Background Often researchers are interested in comparing multiple experimental groups (e.g. tumor size) with a reference group (e.g. normal tissue) on the basis of thousands of features (e.g. genes) and determine if a differentially expressed feature